Alpha Tau Medical LTD.
30
15
18
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
6.7%
2 terminated/withdrawn out of 30 trials
75.0%
-11.6% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (30)
Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
Role: lead
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Role: lead
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients
Role: lead
Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer
Role: lead
Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors
Role: lead
Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety)
Role: lead
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer
Role: lead
Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
Role: lead
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
Role: lead
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma
Role: lead
Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer
Role: lead
Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases
Role: lead
Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer.
Role: lead
Treatment of Locally Recurrent Prostate Cancer
Role: lead
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
Role: lead
Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer
Role: lead
Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer
Role: lead
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
Role: lead
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
Role: lead
A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC
Role: lead